- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06906341
ReloCorilant i kombination med nab-paclitaxel och bevacizumab i avancerad, epitelial äggstocks-, primär peritoneal eller äggledare-rörcancer
En fas 2-studie av relacorilant i kombination med nAb-paclitaxel och bevacizumab i avancerad, epitelial äggstock, primär peritoneal eller äggledare (Bella)
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.
For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Corcept Therapeutics
- Telefonnummer: 650-414-2314
- E-post: corceptstudy557@corcept.com
Studieorter
-
-
-
Brussels, Belgien, 1200
- Rekrytering
- 109
-
Charleroi, Belgien, 6000
- Rekrytering
- 326
-
Hasselt, Belgien, 3500
- Rekrytering
- 325
-
Leuven, Belgien, 3000
- Rekrytering
- 108
-
-
Belgium
-
Aalst, Belgium, Belgien, 9300
- Rekrytering
- 328
-
-
-
-
-
Lille, Frankrike, 59000
- Rekrytering
- 306
-
Nancy, Frankrike, 54100
- Rekrytering
- 307
-
Nice, Frankrike, 06100
- Rekrytering
- 310
-
Pierre-Bénite, Frankrike, 69495
- Rekrytering
- 324
-
Plérin, Frankrike, 22190
- Rekrytering
- 323
-
Toulouse, Frankrike, 31059
- Rekrytering
- 308
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- Rekrytering
- 004
-
-
California
-
Palo Alto, California, Förenta staterna, 94304
- Rekrytering
- 150
-
San Francisco, California, Förenta staterna, 94109
- Rekrytering
- 278
-
San Francisco, California, Förenta staterna, 94143
- Rekrytering
- 014
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Rekrytering
- 032
-
-
Florida
-
Fort Myers, Florida, Förenta staterna, 33901
- Rekrytering
- 544
-
Miami Beach, Florida, Förenta staterna, 33140
- Rekrytering
- 335
-
West Palm Beach, Florida, Förenta staterna, 33041
- Rekrytering
- 543
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- Rekrytering
- 001
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55404
- Rekrytering
- 518
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64132
- Rekrytering
- 334
-
St Louis, Missouri, Förenta staterna, 63110
- Rekrytering
- 521
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 97102
- Rekrytering
- 292
-
-
Ohio
-
Centerville, Ohio, Förenta staterna, 45459
- Rekrytering
- 304
-
-
Oregon
-
Eugene, Oregon, Förenta staterna, 97401
- Rekrytering
- 517
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- Rekrytering
- 127
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Rekrytering
- 522
-
Norfolk, Virginia, Förenta staterna, 23502
- Rekrytering
- 300
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Rekrytering
- 121
-
-
-
-
-
Catania, Italien, 95126
- Rekrytering
- 321
-
Milan, Italien, 20141
- Rekrytering
- 122
-
Milan, Italien, 20159
- Rekrytering
- 516
-
Pavia, Italien, 27100
- Rekrytering
- 295
-
Rome, Italien, 00168
- Rekrytering
- 124
-
Torino, Italien, 10128
- Rekrytering
- 293
-
Treviso, Italien, 31100
- Rekrytering
- 319
-
-
-
-
-
Gdynia, Polen, 81-519
- Rekrytering
- 341
-
Siedlce, Polen, 08-MO
- Rekrytering
- 329
-
-
-
-
-
Badalona, Spanien, 08916
- Rekrytering
- 349
-
Barcelona, Spanien, 08035
- Rekrytering
- 115
-
Madrid, Spanien, 28034
- Rekrytering
- 114
-
Valencia, Spanien, 46026
- Rekrytering
- 330
-
Valencia, Spanien, 46010
- Rekrytering
- 558
-
-
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Sydkorea, 06351
- Rekrytering
- 396
-
-
Goyang-si
-
Gyeonggi-do, Goyang-si, Sydkorea, 10408
- Rekrytering
- 397
-
-
Jongno-gu
-
Seoul, Jongno-gu, Sydkorea, 03080
- Rekrytering
- 399
-
-
Seocho-gu
-
Seoul, Seocho-gu, Sydkorea, 06591
- Rekrytering
- 523
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, Sydkorea, 03722
- Rekrytering
- 398
-
-
Songpa-gu
-
Seoul, Songpa-gu, Sydkorea, 05505
- Rekrytering
- 403
-
-
-
-
-
Aachen, Tyskland, 52074
- Rekrytering
- 519
-
Berlin, Tyskland, 10117
- Rekrytering
- 255
-
Kempten, Tyskland, 87439
- Rekrytering
- 520
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Arms A and B
- Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Arm A Only: Platinum-resistant disease
- Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
- Life expectancy of ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Arm C
- Stage III or IV, recurrent, or metastatic endometrial cancer
- Life expectancy of ≥3 months
- ECOG performance status of 0 or 1
- Able to swallow and retain oral medication
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
- Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Exclusion Criteria:
Arm A and B
- Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
Arm C
- Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
- Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab
In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andra namn:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
Experimentell: Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab
In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andra namn:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
Experimentell: Arm C: Relacorilant in Combination with Nab-Paclitaxel
In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andra namn:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsram: Date of first dose until PD or death, up to 18 months
|
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first. |
Date of first dose until PD or death, up to 18 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Antal patienter med en eller flera biverkningar
Tidsram: Datum för första dosen upp till 30 dagar efter sista dosen
|
Datum för första dosen upp till 30 dagar efter sista dosen
|
|
|
Objective Response Rate (ORR)
Tidsram: Date of first dose until PD or death, up to 18 months
|
To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
Date of first dose until PD or death, up to 18 months
|
|
Best Overall Response Rate (BOR)
Tidsram: Date of first dose until PD or death, up to 18 months
|
To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death. |
Date of first dose until PD or death, up to 18 months
|
|
Duration of Response (DOR)
Tidsram: Time of first objective response until PD or death, up to 18 months
|
To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first. |
Time of first objective response until PD or death, up to 18 months
|
|
Clinical Benefit Rate (CBR)
Tidsram: Week 24
|
To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1. |
Week 24
|
|
Overall Survival (OS)
Tidsram: Date of first dose up to 6, 12, and 18 months
|
To evaluate the probability of OS survival at 6, 12, and 18 months. |
Date of first dose up to 6, 12, and 18 months
|
|
Area under the plasma concentration-time curve (AUC) of relacorilant
Tidsram: On Cycle 1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 1 Day 8 (each cycle is 28 days)
|
|
Maximum plasma concentration (Cmax) of relacorilant
Tidsram: On Cycle1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle1 Day 8 (each cycle is 28 days)
|
|
Trough plasma concentrations (Cmin) of relacorilant
Tidsram: On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Danny Nguyen, MD, Corcept Therapeutics
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- Neoplasmer
- Bevacizumab
- Ovariella neoplasmer
- Paklitaxel
- Relacorilant
- Nab-paklitaxel
- Ovarial
- Neoplasmer efter plats
- Endometrial
- Höggradig
- Ovariella sjukdomar
- Genitala neoplasmer, hona
- Peritoneala neoplasmer
- Äggledarneoplasmer
- Platina resistent
- Endometriell neoplasma
- Äggledarsjukdomar
- Albuminbundet paklitaxel
- Peritoneal eller avancerad äggledare
- Bella
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Urogenitala neoplasmer
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Livmodersjukdomar
- Genitala sjukdomar, kvinnor
- Neoplasmer i endokrina körtel
- Adnexala sjukdomar
- Gonadal sjukdomar
- Uterina neoplasmer
- Peritoneala sjukdomar
- Neoplasmer i buken
- Neoplasmer
- Ovariella neoplasmer
- Endometriella neoplasmer
- Genitala neoplasmer, hona
- Peritoneala neoplasmer
- Äggledarneoplasmer
- Neoplasmer efter plats
- Ovariella sjukdomar
- Äggledarsjukdomar
- Aminosyror, peptider och proteiner
- Proteiner
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Bevacizumab
- 130-nm albuminbunden paklitaxel
- reloce
Andra studie-ID-nummer
- CORT125134-557
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .